Linezolid is superior to vancomycin in experimental pneumonia caused by superantigen-producing Staphylococcus aureus in HLA class II transgenic mice

Melissa J. Karau, Ashenafi Y. Tilahun, Suzannah M. Schmidt, Chad R. Clark, Robin Patel, Govindarajan Rajagopalan

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Superantigens (SAg), the potent activators of the immune system, are important determinants of Staphylococcus aureus virulence and pathogenicity. Superior response to SAg in human leukocyte antigen (HLA)-DR3 transgenic mice rendered them more susceptible than C57BL/6 mice to pneumonia caused by SAg-producing strains of S. aureus. Linezolid, a bacterial protein synthesis inhibitor, was superior to vancomycin in inhibiting SAg production by S. aureus in vitro and conferred greater protection from pneumonia caused by SAg-producing staphylococci.

Original languageEnglish (US)
Pages (from-to)5401-5405
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number10
DOIs
StatePublished - Oct 1 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Linezolid is superior to vancomycin in experimental pneumonia caused by superantigen-producing Staphylococcus aureus in HLA class II transgenic mice'. Together they form a unique fingerprint.

  • Cite this